Our results showed that PARP/HDACi treatment augmented the mRNA levels of CCL5 and CXCL10 in three different TNBC cell lines and MDA-MB-436 tumor-bearing mice (Fig. 5G, H and Fig. S2). This evidence concerns the gene PARP1 and neoplasm.